🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Development of compact transcriptional effectors using high-throughput measurements in diverse contexts go.nature.com/3NMu00N

🧬 Thrilled to share our latest work on engineering precise DNA recombinases for targeted genome integration! Through directed evolution & protein fusions, we achieved over 50% efficiency & 97% specificity for multi-kb DNA cargo insertions. Big thanks to all co-authors -

Incredibly excited that our paper linking single molecule states of TF binding to gene expression using quantitative thermodynamic models is out in Nature today. An amazing collaboration with the Bintu Lab. Congrats to Ben, Michaela, and Julia! nature.com/articles/s4158…

A dream come true: in 2004 I started thinking about counting microstates to predict gene expression with Jane Kondev Rob Phillips Hernan Garcia. 20 years later we can measure them: nature.com/articles/s4158… Thank you William J. Greenleaf Benjamin Doughty Michaela Hinks Julia and all co-authors!

Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent antibody response against a pathogen. Could lead to topical vaccines that are applied in a cream. Djenet Bousbaine led the charge... nature 1/55

Joining the culture war! We tried liquid culture to re-amplify a lenti sgRNA plasmid library from Addgene. N=1 but it wasn't worse than our traditional large plate protocol, and seems even better in uniformity and liquid culture is easier to do thanks Nick Mateyko Carl de Boer

Check out this new preprint showing how to engineer proteins for therapeutics while mitigating immunogenicity!

How Multiplexed Gene Fragments are Expanding What’s Possible in Molecular Biology! Twist Bioscience Josh Tycko Moving Beyond 300 Base Pairs | Twist Bioscience buff.ly/JZ8Ug9E

So excited for the Stylus team and their progress turning recombinases into therapeutics!

Recombinases are simple short proteins that are sufficient to integrate long DNA with high specificity Combined with simple lipid nanoparticles, this could be a way to make durable cell therapies affordable and distributable

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,